nach oben

Neurological Sciences

Erschienen in:

24.11.2020 | COVID-19 | COVID-19 Zur Zeit gratis

Down’s syndrome and COVID-19: risk or protection factor against infection? A molecular and genetic approach

verfasst von: Marcos Altable, Juan Moisés de la Serna

Erschienen in: Neurological Sciences | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Down syndrome (DS) is the most common genetic cause of learning difficulties and intellectual disabilities. DS patients often present with several congenital defects and chronic diseases, including immunity disorders. Elevated levels of pro-inflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor alpha (TNF-α) have been seen, which appear to vary with age. At birth, patients present with combined immunodeficiency, with frequent infections that decrease with age. Furthermore, high levels of IL-4 and IL-10 with anti-inflammatory properties and low levels of IL-6 and TNF-α are described in children. The immune system is believed to play an essential role in SARS-CoV-2 pathogenesis, and it has been associated with elevated levels of pro-inflammatory cytokines and an exaggerated cytokine release syndrome (CRS) that may eventually trigger a severe situation called cytokine storm. On the other hand, genetic features seem to be involved in the predisposition to illness and its severity. Overexpression of DSCR1 and ZAKI-4 inhibits the translocation of activated T lymphocyte nuclear factor (NF-AT) to the nucleus, a main step in the inflammatory responsiveness. We discuss here the possible role of immunology and genetic features of DS in the infection and prognosis in COVID-19.

Kumar M, Thakur AK (2020) Neurological manifestations and comorbidity associated with COVID-19: an overview. Neurol Sci. https://doi.org/10.1007/s10072-020-04823-6

Sultana S, Ananthapur V (2020)COVID-19 and its impact on neurological manifestations and mental health: the present scenario. Neurol Sci 41:3015–3020. https://doi.org/10.1007/s10072-020-04695-wCrossRefPubMed

De Berardis D, Fornaro M, Orsolini L, Valchera A, Carano A, Vellante F et al (2017) Alexithymia and suicide risk in psychiatric disorders: a mini-review. Front Psychiatry 8:148. https://doi.org/10.3389/fpsyt.2017.00148CrossRefPubMedPubMedCentral

Leweke F, Leichsenring F, Kruse J, Hermes S (2011) Is alexithymia associated with specific mental disorders? Psychopathology 45:22–28. https://doi.org/10.1159/000325170CrossRefPubMed

Engel-Yeger B, Muzio C, Rinosi G, Solano P, Geoffroy PA, Pompili M, Amore M, Serafini G (2016) Extreme sensory processing patterns and their relation with clinical conditions among individuals with major affective disorders. Psychiatry Res 236:112–118. https://doi.org/10.1016/j.psychres.2015.12.022CrossRefPubMed

Langdon-Down JLH. On some of the mental affections of childhood and youth being The Lettsomian Lectures delivered before The Medical Society of London in 1887 together with other papers. Ment Affect Child Youth Being Lettsomian Lect Deliv before Med Soc London 1887 Together with Other Pap 1990:1–84

Ballard C, Mobley W, Hardy J, Williams G, Corbett A (2016) Dementia in Down’s syndrome. Lancet Neurol 15:622–636. https://doi.org/10.1016/S1474-4422(16)00063-6CrossRefPubMed

Moreira L, El-Hani CN, Gusmão FAF (2000) A síndrome de Down e sua patogênese: considerações sobre o determinismo genético. Braz J Psychiatry 22:96–99CrossRef

Chapman RS, Hesketh LJ (2000) Behavioral phenotype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev 6:84–95CrossRefPubMed

10.

Loane M, Morris JK, Addor MC, Arriola L, Budd J, Doray B, Garne E, Gatt M, Haeusler M, Khoshnood B, Klungsøyr Melve K, Latos-Bielenska A, McDonnell B, Mullaney C, O’Mahony M, Queißer-Wahrendorf A, Rankin J, Rissmann A, Rounding C, Salvador J, Tucker D, Wellesley D, Yevtushok L, Dolk H (2013)Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur J Hum Genet 21:27–33. https://doi.org/10.1038/ejhg.2012.94CrossRefPubMed

11.

Presson AP, Partyka G, Jensen KM, Devine OJ, Rasmussen SA, McCabe LL et al (2013) Current estimate of Down syndrome population prevalence in the United States. J Pediatr 163:1163–1168CrossRefPubMedPubMedCentral

12.

FAQ and facts about down syndrome-Global Down Syndrome Foundation n.d. https://www.globaldownsyndrome.org/about-down-syndrome/facts-about-down-syndrome/ (accessed 12 July 2020)

13.

Lott IT, Dierssen M (2010) Cognitive deficits and associated neurological complications in individuals with Down’s syndrome. Lancet Neurol 9:623–633. https://doi.org/10.1016/S1474-4422(10)70112-5CrossRefPubMed

14.

Vicari S, Marotta L, Carlesimo GA (2004) Verbal short-term memory in Down’s syndrome: an articulatory loop deficit? J Intellect Disabil Res 48:80–92. https://doi.org/10.1111/j.1365-2788.2004.00478.xCrossRefPubMed

15.

Asim A, Kumar A, Muthuswamy S, Jain S, Agarwal S. Down syndrome: an insight of the disease. J Biomed Sci 2015;22. https://doi.org/10.1186/s12929-015-0138-y, 22

16.

Holmes G (2014) Gastrointestinal disorders in Down syndrome. Gastroenterol Hepatol Bed Bench 7:6PubMedPubMedCentral

17.

Amr NH (2018) Thyroid disorders in subjects with down syndrome: an update. Acta Biomed 89:132–139. https://doi.org/10.23750/abm.v89i1.7120CrossRefPubMedPubMedCentral

18.

Verstegen RHJ, Chang KJJ, Kusters MAA (2020) Clinical implications of immune-mediated diseases in children with Down syndrome. Pediatr Allergy Immunol 31:117–123. https://doi.org/10.1111/pai.13133CrossRefPubMed

19.

Matuszak K, Bryl W, Pupek-Musialik D (2010) Obesity in children and adolescents with mental retardation. Forum Zab Metab 1:55–63

20.

Bartesaghi R, Guide S, Ciani E (2011) Is it possible to improve neurodevelopmental abnormalities in Down syndrome? Rev Neurosci 22:419–455. https://doi.org/10.1515/RNS.2011.037CrossRefPubMed

21.

Teipel SJ, Alexander GE, Schapiro MB, Möller H-J, Rapoport SI, Hampel H (2004)Age-related cortical grey matter reductions in non-demented Down’s syndrome adults determined by MRI with voxel-based morphometry. Brain 127:811–824CrossRefPubMed

22.

Šveljo O, Ćulić M, Koprivšek K, Lučić M (2014) The functional neuroimaging evidence of cerebellar involvement in the simple cognitive task. Brain Imaging Behav 8:480–486. https://doi.org/10.1007/s11682-014-9290-3CrossRefPubMed

23.

Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VLJ et al (2015) A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci 16:564–574CrossRefPubMedPubMedCentral

24.

Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, Lawrence D, Yu LM, Tyrer S, Francis PT, Johnson T, Bullock R, Ballard C (2012) Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 379:528–536. https://doi.org/10.1016/S0140-6736(11)61676-0CrossRefPubMed

25.

Tramutola A, Lanzillotta C, Di Domenico F, Head E, Butterfield DA, Perluigi M et al (2020) Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. Neurobiol Dis 137:104772. https://doi.org/10.1016/j.nbd.2020.104772CrossRefPubMed

26.

Ferreira LSS, Fernandes CS, Vieira MNN, De Felice FG (2018) Insulin resistance in Alzheimer’s disease. Front Neurosci 12:830CrossRefPubMedPubMedCentral

27.

Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, de Felice FG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease-associated Aβ oligomers. J Clin Invest 122:1339–1353. https://doi.org/10.1172/JCI57256CrossRefPubMedPubMedCentral

28.

Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, Sathler LB, Brito-Moreira J, Amaral OB, Silva CA, Freitas-Correa L, Espírito-Santo S, Campello-Costa P, Houzel JC, Klein WL, Holscher C, Carvalheira JB, Silva AM, Velloso LA, Munoz DP, Ferreira ST, de Felice FG (2013)TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer’s β-amyloid oligomers in mice and monkeys. Cell Metab 18:831–843. https://doi.org/10.1016/j.cmet.2013.11.002CrossRefPubMed

29.

Illouz T, Madar R, Biragyn A, Okun E (2019) Restoring microglial and astroglial homeostasis using DNA immunization in a Down syndrome mouse model. Brain Behav Immun 75:163–180. https://doi.org/10.1016/j.bbi.2018.10.004CrossRefPubMed

30.

Salemi M, Barone C, Morale MC, Caniglia S, Romano C, Salluzzo MG, Rando RGG, Ragalmuto A, Bosco P, Romano C (2016)Killer-specific secretory (Ksp37) gene expression in subjects with Down’s syndrome. Neurol Sci 37:793–795. https://doi.org/10.1007/s10072-016-2554-5CrossRefPubMed

31.

Beinke S, Ley SC (2004) Functions of NF-κB1 and NF-κB2 in immune cell biology. Biochem J 382:393–409. https://doi.org/10.1042/BJ20040544CrossRefPubMedPubMedCentral

32.

Salemi M, Barone C, Romano C, Scillato F, Ragalmuto A, Caniglia S, Salluzzo MG, Sciuto G, Ridolfo F, Romano C, Bosco P (2015)NF-kB1 gene expression in Down syndrome patients. Neurol Sci 36:1065–1066. https://doi.org/10.1007/s10072-014-1981-4CrossRefPubMed

33.

WHO | World Health Organization n.d. https://www.who.int/ (accessed 13 July 2020)

34.

Tikellis C, Thomas MC (2012)Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept 2012:1–8CrossRef

35.

Ministerio de Sanidad, Consumo y Bienestar Social - Profesionales - Información científico-técnica, enfermedad por coronavirus, COVID-19 n.d. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/ITCoronavirus/home.htm (accessed 13 July 2020)

36.

Johns Hopkins CSSE. Coronavirus COVID-19(2019-nCoV) 2020. https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 (accessed 7 Mar 2020)

37.

Hornstein NL, Putnam FW (1992) Clinical phenomenology of child and adolescent dissociative disorders. J Am Acad Child Adolesc Psychiatry 31:1077–1085. https://doi.org/10.1097/00004583-199211000-00013CrossRefPubMed

38.

Boukhris M, Hillani A, Moroni F, Annabi MS, Addad F, Ribeiro MH, Mansour S, Zhao X, Ybarra LF, Abbate A, Vilca LM, Azzalini L (2020) Cardiovascular implications of the COVID-19 pandemic: a global perspective. Can J Cardiol 36:1068–1080. https://doi.org/10.1016/j.cjca.2020.05.018CrossRefPubMed

39.

Altable M, de la Serna JM (2020) Cerebrovascular disease in COVID-19: is there a higher risk of stroke? Brain Behav Immun Health 6:100092. https://doi.org/10.1016/j.bbih.2020.100092CrossRefPubMedPubMedCentral

40.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0CrossRefPubMedPubMedCentral

41.

Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y et al (2020) Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. BioRxiv. https://doi.org/10.1101/2020.02.12.945576

42.

Conti P, Ronconi G, Caraffa AL, Gallenga CE, Ross R, Frydas I et al (2020) Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 34:1PubMed

43.

Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS (2018) Cytokine release syndrome. J Immunother Cancer 6:56. https://doi.org/10.1186/s40425-018-0343-9CrossRefPubMedPubMedCentral

44.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3CrossRefPubMedPubMedCentral

45.

Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188–195. https://doi.org/10.1182/blood-2014-05-552729CrossRefPubMedPubMedCentral

46.

Mei H, Hu Y (2020) Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19. Zhonghua Xue Ye Xue Za Zhi 41:185–191. https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0002CrossRefPubMed

47.

Cetiner S, Demirhan O, Inal TC, Tastemir D, Sertdemir Y (2010) Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome. Int J Immunogenet 37:233–237. https://doi.org/10.1111/j.1744-313X.2010.00914.xCrossRefPubMed

48.

Rueda N, Vidal V, García-Cerro S, Narcís JO, Llorens-Martín M, Corrales A, Lantigua S, Iglesias M, Merino J, Merino R, Martínez-Cué C (2018)Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice. Brain Behav Immun 73:235–251. https://doi.org/10.1016/j.bbi.2018.05.008CrossRefPubMed

49.

Castro M, Crinò A, Papadatou B, Purpura M, Giannotti A, Ferretti F, Colistro F, Mottola L, Digilio MC, Lucidi V, Borrelli P (1993) Down’s syndrome and celiac disease: the prevalence of high IgA-antigliadin antibodies and HLA-DR and DQ antigens in trisomy 21. J Pediatr Gastroenterol Nutr 16:265–268CrossRefPubMed

50.

NESPOLI L, BURGIO GR, UGAZIO AG, MACCARIO R (1993) Immunological features of Down’s syndrome: a review. J Intellect Disabil Res 37:543–551. https://doi.org/10.1111/j.1365-2788.1993.tb00324.xCrossRefPubMed

51.

Scotese I, Gaetaniello L, Matarese G, Lecora M, Racioppi L, Pignata C (1998) T cell activation deficiency associated with an aberrant pattern of protein tyrosine phosphorylation after CD3 perturbation in Down’s syndrome. Pediatr Res 44:252–258. https://doi.org/10.1203/00006450-199808000-00019CrossRefPubMed

52.

Beckhaus AA, Castro-Rodriguez JA (2018) Down syndrome and the risk of severe RSV infection: a meta-analysis. Pediatrics 142:e20180225. https://doi.org/10.1542/peds.2018-0225CrossRefPubMed

53.

Pérez-Padilla R, Fernández R, García-Sancho C, Franco-Marina F, Aburto O, López-Gatell H, Bojórquez I (2010) Pandemic (H1N1) 2009 virus and Down syndrome patients. Emerg Infect Dis 16:1312–1314. https://doi.org/10.3201/eid1608.091931CrossRefPubMedPubMedCentral

54.

Krishnan US, Krishnan SS, Jain S, Chavolla-Calderon MB, Lewis M, Chung WK, Rosenzweig EB (2020)SARS-CoV-2 infection in patients with Down syndrome, congenital heart disease, and pulmonary hypertension: is Down syndrome a risk factor? J Pediatr 225:246–248. https://doi.org/10.1016/j.jpeds.2020.06.076CrossRefPubMedPubMedCentral

55.

Espinosa JM (2020) Down syndrome and COVID-19: a perfect storm? Cell Rep Med 1:100019. https://doi.org/10.1016/j.xcrm.2020.100019CrossRefPubMedPubMedCentral

56.

De Weerd NA, Nguyen T (2012) The interferons and their receptors-distribution and regulation. Immunol Cell Biol 90:483–491. https://doi.org/10.1038/icb.2012.9CrossRefPubMedPubMedCentral

57.

Duan ZP, Chen Y, Zhang J, Zhao J, Lang ZW, Meng FK et al (2003) Clinical characteristics and mechanism of liver injury in patients with severe acute respiratory syndrome. Zhonghua Gan Zang Bing Za Zhi= Zhonghua Ganzangbing Zazhi= Chin J Hepatol 11:493

58.

Verstegen RHJ, Kusters MAA (2020) Inborn errors of adaptive immunity in Down syndrome. J Clin Immunol 40:791–806. https://doi.org/10.1007/s10875-020-00805-7CrossRefPubMed

59.

Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, Smith KP, Liggett LA, Gomez EB, Galbraith MD, DeGregori J, Espinosa JM (2016) Trisomy 21 consistently activates the interferon response. Elife 5. https://doi.org/10.7554/eLife.16220

60.

Cytokine storm and the H5N1 influenza pandemic: the bird flu n.d. http://www.cytokinestorm.com/ (accessed 13 July 2020)

61.

Hasle H, Friedman JM, Olsen JH, Rasmussen SA (2016) Low risk of solid tumors in persons with Down syndrome. Genet Med 18:1151–1157. https://doi.org/10.1038/gim.2016.23CrossRefPubMed

62.

Satgé D, Seidel MG (2018) The pattern of malignancies in down syndrome and its potential context with the immune system. Front Immunol 9. https://doi.org/10.3389/fimmu.2018.03058

63.

Strippoli P, Lenzi L, Petrini M, Carinci P, Zannotti M (2000) A new gene family including DSCR1 (Down syndrome candidate region 1) and ZAKI-4: characterization from yeast to human and identification of DSCR1-like 2, a novel human member (DSCR1L2). Genomics 64:252–263. https://doi.org/10.1006/geno.2000.6127CrossRefPubMed

64.

Liddicoat AM, Lavelle EC (2019) Modulation of innate immunity by cyclosporine A. Biochem Pharmacol 163:472–480. https://doi.org/10.1016/j.bcp.2019.03.022CrossRefPubMed

65.

Pfefferle S, Schöpf J, Kögl M, Friedel CC, Müller MA, Carbajo-Lozoya J, Stellberger T, von Dall’Armi E, Herzog P, Kallies S, Niemeyer D, Ditt V, Kuri T, Züst R, Pumpor K, Hilgenfeld R, Schwarz F, Zimmer R, Steffen I, Weber F, Thiel V, Herrler G, Thiel HJ, Schwegmann-Weßels C, Pöhlmann S, Haas J, Drosten C, von Brunn A (2011) The SARS-Coronavirus-host interactome: identification of cyclophilins as target for pan-Coronavirus inhibitors. PLoS Pathog 7:e1002331. https://doi.org/10.1371/journal.ppat.1002331CrossRefPubMedPubMedCentral

66.

Feske S, Giltnane J, Dolmetsch R, Staudt LM, Rao A (2001) Gene regulation mediated by calcium signals in T lymphocytes. Nat Immunol 2:316–324. https://doi.org/10.1038/86318CrossRefPubMed

67.

Hogan PG, Chen L, Nardone J, Rao A (2003) Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17:2205–2232. https://doi.org/10.1101/gad.1102703CrossRefPubMed

68.

Mousavizadeh L, Ghasemi S (2020) Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect. https://doi.org/10.1016/j.jmii.2020.03.022

69.

Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q, Wu J (2020) Coronavirus infections and immune responses. J Med Virol 92:424–432CrossRefPubMedPubMedCentral

70.

Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS et al (2020) SARS-CoV-2, SARS-CoV, and MERS-CoV: a comparative overview. Infez Med 28:174–184PubMed

71.

Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT, Kim SJ (2020) Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol 30:313–324. https://doi.org/10.4014/jmb.2003.03011CrossRefPubMed

72.

Chen Y, Liu Q, Guo D (2020) Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 92:418–423. https://doi.org/10.1002/jmv.25681CrossRefPubMedPubMedCentral

73.

Rokni M, Ghasemi V, Tavakoli Z (2020) Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: comparison with SARS and MERS. Rev Med Virol 30:e2107. https://doi.org/10.1002/rmv.2107CrossRefPubMedPubMedCentral

74.

Han Q, Lin Q, Jin S, You L (2020) Coronavirus 2019-nCoV: a brief perspective from the front line. J Inf Secur 80:373–377. https://doi.org/10.1016/j.jinf.2020.02.010CrossRef

75.

Malle L, Gao C, Bouvier N, Percha B (2020) Bogunovic D (2020)COVID-19 hospitalization is more frequent and severe in Down syndrome. MedRxiv 05(26):20112748. https://doi.org/10.1101/2020.05.26.20112748CrossRef

76.

Zigman WB (2013) Atypical aging in down syndrome. Dev Disabil Res Rev 18:51–67. https://doi.org/10.1002/ddrr.1128CrossRefPubMed

Titel: Down’s syndrome and COVID-19: risk or protection factor against infection? A molecular and genetic approach
verfasst von: Marcos Altable
Juan Moisés de la Serna
Publikationsdatum: 24.11.2020
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Neurological Sciences / Ausgabe 2/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04880-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Down’s syndrome and COVID-19: risk or protection factor against infection? A molecular and genetic approach

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Acute cognitive disorder as the initial manifestation of nitrous oxide abusing: a case report

Magnetic resonance-guided focused ultrasound for Parkinson’s disease since ExAblate, 2016–2019: a systematic review

DAPT score: predictive model of dual-antiplatelet therapy for acute cerebral infarction

Changed pattern of hospital admission in stroke during COVID-19 pandemic period in Iran: a retrospective study

Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome

Ethical considerations in neurology during the COVID-19 pandemic

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Update Neurologie